Anti-phospholipid syndrome in seven leprosy patients with thrombotic events on corticosteroid and/or thalidomide regimen: insights on genetic and laboratory profiles

AUTOR(ES)

Vernal, Sebastian, Brochado, Maria Jose Franco, Bueno-Filho, Roberto, Louzada-Junior, Paulo, Roselino, Ana Maria

FONTE

Rev. Soc. Bras. Med. Trop.

DATA DE PUBLICAÇÃO

2018-02

RESUMO

Abstract INTRODUCTION Corticosteroids and/or thalidomides have been associated with thromboembolism events (TBE) in multibacillary (MB) leprosy. This report aimed to determine genetic and laboratory profiles associated with leprosy and TBE. METHODS Antiphospholipid antibodies (aPL), coagulation-related exams, prothrombin and Leiden’s factor V mutations, and ß2-glycoprotein-I (ß2GPI) Val247Leu polymorphism were assessed. RESULTS Six out of seven patients with leprosy were treated with prednisone and/or thalidomide during TBE and presented at least one positive aPL. All patients presented ß2GPI polymorphism, and one showed prothrombin mutation. CONCLUSIONS Corticosteroid or thalidomide adverse effects and aPL and ß2GPI polymorphisms may cause TBE in patients with MB leprosy.

Documentos Relacionados

• Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.
• Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
• Adverse events in patients with leprosy on treatment with thalidomide
• Clinical manifestations of the anti‐phospholipid syndrome as defined by the updated Sapporo classification criteria
• Ischaemic optic neuropathy, transverse myelitis, and epilepsy in an anti-phospholipid positive patient with systemic lupus erythematosus.